News | May 24, 2025
CPHI & PMEC China sees surge in international attendance
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
EBITDA for the period rose by 23.2% to Rs. 3,797 million
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
She has held senior positions at Coca-Cola in China and PepsiCo in India
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
EBITDA before special items decreases to €4.08 billion (7.4%)
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Subscribe To Our Newsletter & Stay Updated
